Adc Therapeutics Sa · NYSE:ADCT
Adc Therapeutics Sa — Q1 2023 Earnings Presentation
13 slides from Adc Therapeutics Sa's earnings presentation, May 9, 2023
Slide 1: 1Q 2023 Earnings Call
1Q 2023 Earnings Call May 9, 2023
Slide 2: Forward-Looking Statements
Forward-Looking Statements This presentation and any accompanying oral presentation have been prepared by ADC Therapeutics SA ("ADC Therapeutics“, “we” or “us”) for informational purposes only and not for any other purpose. Nothing contained in this presentation is, or should be construed as, a reco
Slide 3: Agenda
Agenda 01 Ameet Mallik Introduction Chief Executive Officer Kristen Harrington-Smith Commercial Highlights 02 Chief Commercial Officer Mohamed Zaki Clinical Highlights 03 Chief Medical Officer Pepe Carmona 04 Chief Financial Officer Financial Update 3
Slide 4: Updated Corporate & Capital Allocation Strategy
Updated Corporate & Capital Allocation Strategy New § Net product sales: $19.0M in 1Q 2023, +15% yr/yr and slight decline qtr/qtr, including higher gross-to-net deductions ZYNLONTA® § Expect to grow FY 2023 net sales by double-digit percentage yr/yr Commercial § Implementing new go-to-market model t
Slide 5: ZYNLONTA: 1Q 2023 Net Sales of $19M, up 15% yr/yr
ZYNLONTA: 1Q 2023 Net Sales of $19M, up 15% yr/yr Net Product Sales ($M) 19.0 Increasing awareness and trial Incremental growth in both the +15% academic and community settings 16.5 Higher gross-to-net sales deductions 1Q 2022 1Q 2023 5
Slide 6: Responding to Evolving Market Dynamics in 3L+ DLBCL
Responding to Evolving Market Dynamics in 3L+ DLBCL § Fragmented market with no standard of care (systemic chemo- § Academic centers expanding based therapy in large portion of into community through patients) Competitive acquisition/partnerships § Pola-RCHP in 1L expected to open trends § Consolida
Slide 7: New Go-to-Market Model Aligned to Local Healthcare Ecosystems
New Go-to-Market Model Aligned to Local Healthcare Ecosystems Previous model: New go-to-market model: § Sales regions based only on § Focus on local healthcare ecosystems including geography academic and community centers § Traditional structure of line § Entire field force to have customer-facing r
Slide 8: Developing ZYNLONTA to be the Combination Agent of Choice in Earlier Lines of Therapy
Developing ZYNLONTA to be the Combination Agent of Choice in Earlier Lines of Therapy Initial data expected in 1H 2024 Novel § LOTIS-7: Phase 1 trial of ZYNLONTA in combinations combination with glofitamab, mosunetuzumab Initial data expected and polatuzumab (Roche supply agreement) by end of 2023 §
Slide 9: Prioritized Pipeline of More Advanced Programs with Nearer-Term Data Readouts
Prioritized Pipeline of More Advanced Programs with Nearer-Term Data Readouts § Validated target shown to be well-suited for an ADC approach ADCT-601 § Phase 1b study: Initially focus on single-agent activity (sarcoma and NSCLC); IHC assay being finalized Targeting AXL § Initial data from Phase 1 st
Slide 10: 1Q 2023 Financial Update (in $ millions)
1Q 2023 Financial Update (in $ millions) Cash runway expected to extend into mid-2025 based on current business plan Pro forma cash of $386M including $75M expected from Health Care Royalty Partners Balance Sheet March 31, 2023 Cash and cash equivalents $310.5 Statement of Operations 1Q 2023 % vs. 1
Slide 11: FY 2023 Guidance
FY 2023 Guidance Net Product Sales ($M) Double-Digit Net Product Sales: Expect double-digit percentage % Growth growth yr/yr This includes a gross-to-net increase as compared to 2022 of: 75 § Approximately 2 to 3 percentage points related to Group Purchasing Organization (GPO) contracting § Mid-to-h
Slide 12: Multiple Value-Driving Catalysts Expected in 2023 and 2024
Multiple Value-Driving Catalysts Expected in 2023 and 2024 Maximizing the ZYNLONTA Opportunity q 2023: Grow U.S. ZYNLONTA net sales by a double-digit percentage yr/yr and achieve commercial brand profitability q 2Q 2023: European launch by partner Sobi q Year-end 2023: Initial data from LOTIS-9 stud
Slide 13: 1Q 2023 Earnings Call
1Q 2023 Earnings Call THERAPEUTICS Innovating Science. Inspiring Hope.